When should CT scans and surveillance be repeated in a patient with stage 3b invasive ductal carcinoma after chemotherapy and modified radical mastectomy who is on ongoing hormonal therapy?

Surveillance Schedule for Stage 3B Invasive Ductal Carcinoma Post-Treatment

For your stage 3B IDC patient who has completed chemotherapy and modified radical mastectomy and is on ongoing hormonal therapy, perform history and physical examination every 3-6 months for the first 3 years, then every 6-12 months for years 4-5, and annually thereafter, with annual mammography of the remaining breast only—routine CT scans are NOT recommended for asymptomatic surveillance. 1, 2

Clinical Examination Schedule

The cornerstone of surveillance is regular clinical assessment, not imaging:

• Years 1-3: Every 3-6 months
• Years 4-5: Every 6-12 months
• Year 6 onward: Annually

Each visit should include:

• Detailed symptom review (new pain, cough, weight loss, neurologic symptoms)
• Thorough physical examination of chest wall, remaining breast, lymph node basins
• Assessment of hormonal therapy adherence and side effects
• Bone health monitoring (given aromatase inhibitor use)

1, 2

Imaging Recommendations

Mammography

• Annual mammography of the contralateral (remaining) breast is the only routine imaging recommended
• No mammography needed on mastectomy side
• Continue annually for life

1, 3, 2

CT Scans - NOT Recommended

Routine chest, abdomen, or pelvis CT scans are explicitly NOT recommended for asymptomatic surveillance, even in stage 3B disease. 1, 2 The ASCO guidelines are unequivocal on this point—multiple randomized trials have shown that intensive surveillance with CT imaging does not improve overall survival or quality of life compared to clinical examination and mammography alone. 1

Recent research from 2023 confirms this remains true in the modern era of improved systemic therapies—alternative follow-up with regular chest or abdominal imaging showed no survival benefit over standard follow-up (mean OS 154.5 vs 151.9 months, p=0.54). 4

When to Order CT Scans

CT imaging should be reserved for:

• New symptoms (persistent bone pain, dyspnea, abdominal pain, headaches)
• Abnormal physical examination findings (palpable masses, hepatomegaly, focal neurologic signs)
• Elevated tumor markers if being followed (though routine marker testing is also not recommended)
• Abnormal laboratory values suggesting metastatic disease

1, 2

Laboratory Testing - Also NOT Recommended

Do not routinely order:

• Complete blood counts
• Chemistry panels
• Liver function tests
• Tumor markers (CEA, CA 15-3, CA 27.29)
• Bone scans

These should only be obtained if clinically indicated by symptoms or examination findings. 1, 2

Critical Nuances for Stage 3B Disease

While your patient has locally advanced disease (stage 3B), the evidence does not support more intensive imaging surveillance even in this higher-risk population. The rationale is that:

1. Most recurrences are detected by symptoms or examination, not by imaging in asymptomatic patients 4, 5
2. Early detection of metastatic disease has not been shown to improve survival in randomized trials 1
3. Intensive surveillance increases costs, anxiety, and false-positive findings without mortality benefit 6

The highest risk period is the first 2-3 years post-treatment, which is why clinical examinations are more frequent during this window. 2, 5

Hormonal Therapy Monitoring

Since your patient is on ongoing hormonal therapy, specific monitoring includes:

• Adherence assessment at each visit (critical for outcomes)
• Bone density monitoring if on aromatase inhibitor (baseline and periodic DEXA scans)
• Gynecologic screening if on tamoxifen (though routine pelvic ultrasound not recommended)
• Cardiovascular risk assessment given prior anthracycline/HER2-targeted therapy exposure

3, 2

Common Pitfall to Avoid

The most common error is ordering "routine" surveillance CT scans every 3-6 months in high-risk patients. This practice is not evidence-based and contradicts all major guideline recommendations. 1, 2 While it may seem intuitive that earlier detection would improve outcomes, multiple trials have failed to demonstrate this benefit, and the harms (radiation exposure, false positives, unnecessary biopsies, anxiety) are real.

Duration of Surveillance

Continue this surveillance schedule indefinitely, as late recurrences can occur beyond 5 years, particularly with hormone receptor-positive disease on endocrine therapy. 3, 2 However, the intensity decreases after year 5 to annual visits.